Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis

Exclusion Criteria

• •1. Combined with one of cerebrovascular disease, spinal cord disease, spinal muscular atrophy, juvenile myoatrophy of distal upper extremity, multifocal motor neuropathy, Kennedy disease, epilepsy, etc;
• •2. Severe renal insufficiency: creatinine clearance rate \<30 mL/min (Cockcroft-Gault formula, urea nitrogen and (or) blood creatinine\> 1.5 times the upper limit of normal, or other known severe renal insufficiency diseases;
• •3. Severe liver damage: ALT, AST\> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic hepatitis, cirrhosis, etc.;
• •4. Obvious tachycardia or bradycardia; patients with acute myocardial infarction or interventional therapy in the past 6 months (patients with grade III-IV according to NYHA classification);
• •5. Combined with malignant tumor, blood, digestion or other serious diseases;
• •6. Female patients during pregnancy and lactation;
• •7. Participated in other clinical trials within 30 days before randomization, or are participating in other clinical trials;